Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for \u20b9325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market.<\/p>\n
Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in the areas of oncology and non-oncology. The company has a strong product portfolio in the non-oncology segment, with a focus on therapeutic areas such as neurology, cardiology, and gastroenterology. The non-oncology business of Khandelwal Laboratories includes a range of products, including tablets, capsules, and injectables.<\/p>\n
The acquisition of Khandelwal Laboratories’ non-oncology business will add over 50 products to Aurobindo Pharma’s portfolio, including some well-established brands. The products will be marketed and distributed by Aurobindo Pharma’s existing sales team, which has a strong presence in the domestic market. The acquisition is expected to be completed in the next few months, subject to regulatory approvals.<\/p>\n
Aurobindo Pharma has stated that the acquisition is in line with its strategy to expand its product portfolio and increase its presence in the domestic market. The company has been looking to strengthen its position in the Indian market, where it faces intense competition from other pharmaceutical companies. The acquisition of Khandelwal Laboratories’ non-oncology business is expected to help Aurobindo Pharma achieve this objective.<\/p>\n
The acquisition is also expected to be beneficial for Khandelwal Laboratories, as it will allow the company to focus on its oncology business. Khandelwal Laboratories has a strong presence in the oncology segment, and the company is expected to use the proceeds from the sale to invest in its oncology business.<\/p>\n
The deal is valued at \u20b9325 crore, which is a significant amount for a pharmaceutical company of Khandelwal Laboratories’ size. The acquisition price includes the cost of acquiring the non-oncology business, including the products, manufacturing facilities, and marketing rights. Aurobindo Pharma has stated that the acquisition will be funded through a combination of internal accruals and debt.<\/p>\n
Overall, the acquisition of Khandelwal Laboratories’ non-oncology business by Aurobindo Pharma is a significant development in the Indian pharmaceutical industry. The deal is expected to strengthen Aurobindo Pharma’s position in the domestic market and provide the company with a strong portfolio of products in the non-oncology segment.<\/p>\n","protected":false},"excerpt":{"rendered":"
Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for \u20b9325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market. Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in the areas of oncology and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[21,2],"tags":[],"class_list":["post-89791","post","type-post","status-publish","format-standard","hentry","category-aurobindo-pharma","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89749,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/aurobindo-pharma-pushes-back-deadline-to-purchase-26-stake-in-swarnaakshu-solar\/","url_meta":{"origin":89791,"position":0},"title":"Aurobindo Pharma Pushes Back Deadline to Purchase 26% Stake in Swarnaakshu Solar","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma's strategy to diversify its business and invest in renewable energy. The company had initially planned to complete the acquisition by a certain deadline, but it\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89658,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/13\/will-aurobindo-pharma-limiteds-new-product-launches-drive-revenue-growth-in-year-quarterly-earnings-analysis-profit-outlook-on-earlytimes-in\/","url_meta":{"origin":89791,"position":1},"title":"Will Aurobindo Pharma Limited’s New Product Launches Drive Revenue Growth in YEAR – Quarterly Earnings Analysis & Profit Outlook on earlytimes.in","author":"Team Small News","date":"December 13, 2025","format":false,"excerpt":"Aurobindo Pharma Limited, a leading pharmaceutical company, is expected to witness a significant boost in revenue due to the launch of new products. The company has been consistently expanding its product portfolio, and the latest launches are anticipated to contribute substantially to its top-line growth. In this article, we will\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89791,"position":2},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89764,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/biocon-biologics-enhances-its-cancer-treatment-offerings-with-the-introduction-of-three-key-biosimilar-products\/","url_meta":{"origin":89791,"position":3},"title":"Biocon Biologics enhances its cancer treatment offerings with the introduction of three key biosimilar products.","author":"Team Small News","date":"January 7, 2026","format":false,"excerpt":"Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab\/Hyaluronidase, Nivolumab, and Pembrolizumab, which are used to treat various types of cancer. With these new additions, Biocon\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89778,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/10\/mylan-and-aurobindo-pharma-must-defend-against-allegations-of-colluding-to-fix-prices-for-generic-drugs\/","url_meta":{"origin":89791,"position":4},"title":"Mylan and Aurobindo Pharma must defend against allegations of colluding to fix prices for generic drugs.","author":"Team Small News","date":"January 10, 2026","format":false,"excerpt":"A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether the companies conspired to fix drug prices. This decision\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89682,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/18\/glenmark-secures-1-billion-deal-for-multi-regional-rights-to-hansoh-pharmas-cancer-treatment-medication\/","url_meta":{"origin":89791,"position":5},"title":"Glenmark secures $1 billion deal for multi-regional rights to Hansoh Pharma’s cancer treatment medication.","author":"Team Small News","date":"December 18, 2025","format":false,"excerpt":"Glenmark Specialty S.A., a subsidiary of India-based Glenmark Pharmaceuticals, has entered into a licensing agreement with China's Jiangsu Hansoh Pharmaceutical Group Co. for the oncology drug Aumolertinib. The agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib in several high-potential markets, including the Middle East, Africa, Southeast and South\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89791"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89791\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}